[Search for new anti-angiogenic agents with structural analogy with thalidomide].
Despite its teratogenic effects, thalidomide has been reintroduced in human anticancer treatment for its anti-angiogenic activity, especially observed in patients with multiple myeloma. Here, we report the synthesis of new analogues designed to increase the thalidomide anti-tumour properties. The anti-angiogenic activity of the compounds was tested on EA.hy 926 endothelial cell lines. In this model, that is easier to manipulate than HUVEC cells, thalidomide is active in a similar dose range as reported on HUVEC cells and one of our compounds is more efficient.
Vidal
M
M
Laboratoire de chimie organique, UFR des sciences pharmaceutiques et biologiques, 4, avenue de l'Observatoire, F75270 Paris Cedex 06, France.
Gasse
C
C
Garbay
Chr
C
Galons
H
H
D020533:Angiogenesis Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology*; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D042783:Endothelial Cells / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010766:Phosphorylation; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology*
D020533:Angiogenesis Inhibitors; D013792:Thalidomide